Establishing Africa's first thermostable, locally manufactured animal vaccine facility — reducing import dependence, protecting food security, and positioning Zambia as a regional biosecurity hub across Southern Africa.
Zambia's animal production sector — spanning smallholder and commercial poultry and livestock — is a critical engine of food security, rural income, and national economic growth. Yet recurrent disease outbreaks continue to erode productivity and sustain deep dependence on imported veterinary vaccines.
Imported vaccines are frequently ill-matched to locally circulating strains and are constrained by fragile cold-chain infrastructure, severely limiting their effectiveness in rural and pastoral settings where disease pressure is highest.
This initiative proposes the establishment of a thermostable animal vaccine R&D and manufacturing facility in Zambia — structured through a public-private partnership model under a hybrid university-based incubation and joint-venture governance framework, with the Industrial Development Corporation (IDC) of Zambia as primary institutional anchor.
Local manufacturing will reduce import dependence, improve vaccine effectiveness under field conditions, create high-quality scientific employment, and position Zambia as a regional vaccine supply hub across Southern Africa. The project aligns with Zambia's national industrialization goals and strengthens global One Health, biosecurity, and pandemic prevention frameworks.
One Health infrastructure that creates economic value, protects livelihoods, and builds lasting regional capacity.
Protecting poultry and livestock from devastating disease outbreaks that erode smallholder livelihoods and commercial operations across Zambia.
Skilled scientific employment and import substitution across the vaccine value chain, retaining economic value within Zambia's borders.
Strengthening One Health biosecurity at the animal–human interface, reducing spillover risk and aligning with global health security frameworks.
Positioning Zambia as the SADC hub for thermostable animal vaccines — exporting cold-chain-free solutions to neighboring countries.
Phase 1 focuses on the two highest-burden, highest-impact diseases in Zambia's animal health landscape.
The facility is designed with modular, scalable architecture to accommodate future expansion into Infectious Bursal Disease (IBD), Infectious Bronchitis (IB), Avian Influenza (AI), and other high-priority diseases as capacity and market demand grow.
A disciplined, milestone-driven pathway from feasibility to commercial-scale thermostable vaccine production.
Seven specialists bringing complementary expertise spanning vaccine science, One Health, Zambian clinical research, regulatory affairs, and immunization strategy.
We are seeking feasibility-phase funding and strategic partners to unlock this transformational initiative. Your investment will directly reduce disease burden, protect food security, and build lasting scientific capacity in Zambia and across Southern Africa.